170 related articles for article (PubMed ID: 37920686)
1. Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study.
Carrión L; Clemente-Sánchez A; Márquez-Pérez L; Orcajo-Rincón J; Rotger A; Ramón-Botella E; González-Leyte M; Echenagusía-Boyra M; Luis Colón A; Reguera-Berenguer L; Bañares R; Rincón D; Matilla-Peña A
Therap Adv Gastroenterol; 2023; 16():17562848231206995. PubMed ID: 37920686
[TBL] [Abstract][Full Text] [Related]
2. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
Reincke M; Schultheiss M; Doppler M; Verloh N; Uller W; Sturm L; Thimme R; Goetz C; Bettinger D
Hepatol Commun; 2022 Nov; 6(11):3223-3233. PubMed ID: 36064940
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
4. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
5. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
7. CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma.
Romero-Cristóbal M; Clemente-Sánchez A; Ramón E; Téllez L; Canales E; Ortega-Lobete O; Velilla-Aparicio E; Catalina MV; Ibáñez-Samaniego L; Alonso S; Colón A; Matilla AM; Salcedo M; Albillos A; Bañares R; Rincón D
JHEP Rep; 2023 Mar; 5(3):100645. PubMed ID: 36691569
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
9. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
10. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
12. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.
Hur MH; Cho Y; Kim DY; Lee JS; Kim GM; Kim HC; Sinn DH; Hyun D; Lee HA; Seo YS; Lee IJ; Park JW; Kim YJ
Clin Mol Hepatol; 2023 Jul; 29(3):763-778. PubMed ID: 37254488
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
14. Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.
Azoulay D; Ramos E; Casellas-Robert M; Salloum C; Lladó L; Nadler R; Busquets J; Caula-Freixa C; Mils K; Lopez-Ben S; Figueras J; Lim C
JHEP Rep; 2021 Feb; 3(1):100190. PubMed ID: 33294830
[TBL] [Abstract][Full Text] [Related]
15. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
Cappelli A; Pettinato C; Golfieri R
J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
[TBL] [Abstract][Full Text] [Related]
16. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression.
Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957
[TBL] [Abstract][Full Text] [Related]
17. Radioembolization of hepatocarcinoma with
Chiesa C; Mira M; Bhoori S; Bormolini G; Maccauro M; Spreafico C; Cascella T; Cavallo A; De Nile MC; Mazzaglia S; Capozza A; Tagliabue G; Brusa A; Marchianò A; Seregni E; Mazzaferro V
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
[TBL] [Abstract][Full Text] [Related]
18. Induction of Contralateral Hepatic Hypertrophy by Unilobar Yttrium-90 Transarterial Radioembolization versus Portal Vein Embolization: An Animal Study.
Liebl M; Pedersoli F; Zimmermann M; Schulze-Hagen M; Truhn D; Sieben P; von Stillfried S; Tschinaev A; Heinzel A; Kuhl CK; Bruners P; Isfort P
J Vasc Interv Radiol; 2021 Jun; 32(6):836-842.e2. PubMed ID: 33689835
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis.
Martelletti C; Ricotti A; Gesualdo M; Carucci P; Gaia S; Rolle E; Burlone ME; Okolicsanyi S; Mattalia A; Pirisi M; Berchialla P; Tabone M
J Dig Dis; 2021 Aug; 22(8):496-502. PubMed ID: 34189839
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
